Research had indicated that the atypical activation of CTNNB1 was linked to the development of various types of tumors, including but not limited to colorectal cancer, ovarian cancer, prostate cancer, hepatoblastoma, and hepatocellular carcinoma (40). Here, CTNNB1 is linked to prostate cancer.